Molecular Medicine

, Volume 17, Issue 5–6, pp 426–433 | Cite as

Inhibition of Histone Deacetylases in Inflammatory Bowel Diseases

  • Rainer Glauben
  • Britta Siegmund
Review Article


This review, comprised of our own data and that of others, provides a summary overview of histone deacetylase (HDAC) inhibition on intestinal inflammation as well as inflammation-mediated carcinogenesis. Experimental colitis in mice represents an excellent in vivo model to define the specific cell populations and target tissues modulated by inhibitors of HDAC. Oral administration of either suberyolanilide hydroxamic acid (SAHA) or ITF2357 results in an amelioration in these models, as indicated by a significantly reduced colitis disease score and histological score. This effect was paralleled by suppression of proinflammatory cytokines at the site of inflammation as well as specific changes in the composition of cells within the lamina propria. In addition, tumor number and size was significantly reduced in two models of inflammation-driven tumorigenesis, namely interleukin (IL)-10-deficient mice and the azoxymethane-dextran sulfate sodium (DSS) model, respectively. The mechanisms affected by HDAC inhibition, contributing to this antiinflammatory and antiproliferative potency will be discussed in detail. Furthermore, with regard to the relevance in human inflammatory bowel disease, the doses of ITF2357 considered safe in humans and the corresponding serum concentrations are consistent with the efficacious dosing used in our in vivo as well as in vitro experiments. Thus, the data strongly suggest that HDAC inhibitors could serve as a therapeutic option in inflammatory bowel disease.


  1. 1.
    Mathew CG. (2008) New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat. Rev. Genet. 9:9–14.CrossRefGoogle Scholar
  2. 2.
    Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–40.CrossRefGoogle Scholar
  3. 3.
    Soderlund S, et al. (2009). Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 136:1561–67.CrossRefGoogle Scholar
  4. 4.
    Karin M, Greten FR. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749–59.CrossRefGoogle Scholar
  5. 5.
    Tarmin L, et al. (1995) Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:2035–8.PubMedGoogle Scholar
  6. 6.
    Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353–362.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 325:834–40.CrossRefGoogle Scholar
  8. 8.
    Norris KL, Lee JY, Yao TP. (2009) Acetylation goes global: the emergence of acetylation biology. Sci. Signal. 2:pe76.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Spange S, Wagner T, Heinzel T, Kramer OH. (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41:185–98.CrossRefGoogle Scholar
  10. 10.
    Fuss IJ, et al. (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490–7.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Fuss IJ, et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261–70.PubMedGoogle Scholar
  12. 12.
    Stuber E, Strober W, Neurath M. (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693–8.CrossRefGoogle Scholar
  13. 13.
    Weaver CT, Hatton RD, Mangan PR, Harrington LE. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821–52.CrossRefGoogle Scholar
  14. 14.
    Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942–9.CrossRefGoogle Scholar
  15. 15.
    Zhang X, et al. (2011) Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect. Immun. 79:527–41.CrossRefGoogle Scholar
  16. 16.
    Zhou L, et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967–74.CrossRefGoogle Scholar
  17. 17.
    Fujino S, et al. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65–70.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Fuss IJ, et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12:9–15.CrossRefGoogle Scholar
  19. 19.
    Umetsu DT, DeKruyff RH. (1997) Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Proc. Soc. Exp. Biol. Med. 215:11–20.CrossRefGoogle Scholar
  20. 20.
    Bouma G, Strober W. (2003) The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521–33.CrossRefGoogle Scholar
  21. 21.
    Heller F, et al. (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 129:550–64.CrossRefGoogle Scholar
  22. 22.
    Stephens GL, Shevach EM. (2007) Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity. 27:417–9.CrossRefGoogle Scholar
  23. 23.
    Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8:457–62.CrossRefGoogle Scholar
  24. 24.
    Ruemmele FM, Brousse N, Goulet O. (2004) Autoimmune enteropathy: molecular concepts. Curr. Opin. Gastroenterol. 20:587–91.CrossRefGoogle Scholar
  25. 25.
    Ochs HD, Gambineri E, Torgerson TR. (2007) IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38:112–21.CrossRefGoogle Scholar
  26. 26.
    McDonel P, Costello I, Hendrich B. (2009) Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 41:108–16.CrossRefGoogle Scholar
  27. 27.
    Grozinger CM, Hassig CA, Schreiber SL. (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U. S. A. 96:4868–73.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Feng Q, Zhang Y. (2001) The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15:827–832.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Chang S, Collins PL, Aune TM. (2008) T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation. J. Immunol. 181:8372–81.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Chen GY, Osada H, Santamaria-Babi LF, Kannagi R (2006) Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 103:16894–9.CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Sarra M, Pallone F, Macdonald TT, Monteleone G. (2010) IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16:1808–13.CrossRefGoogle Scholar
  32. 32.
    Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673–81.CrossRefGoogle Scholar
  33. 33.
    Moreira JM, Scheipers P, Sorensen P. (2003) The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer. 3:30.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7:1422–32.CrossRefGoogle Scholar
  35. 35.
    Koenen HJ, et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 112:2340–52.CrossRefGoogle Scholar
  36. 36.
    Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug. Discov. 8:969–81.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299–307.CrossRefGoogle Scholar
  38. 38.
    Wang L, Tao R, Hancock WW. (2009) Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87:195–202.CrossRefGoogle Scholar
  39. 39.
    de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583–94.CrossRefGoogle Scholar
  40. 40.
    Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84:1540–8.CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Jung ID, et al. (2009) Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int. J. Immunopathol. Pharmacol. 22:501–15.CrossRefGoogle Scholar
  42. 42.
    Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123–30.CrossRefGoogle Scholar
  43. 43.
    Sun Y, et al. (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182:5899–903.CrossRefGoogle Scholar
  44. 44.
    Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562–73.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Aung HT, et al. (2006) LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 20:1315–27.CrossRefGoogle Scholar
  46. 46.
    Deng WG, Zhu Y, Wu KK. (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 103:2135–42.CrossRefGoogle Scholar
  47. 47.
    Ito K, et al. (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203:7–13.CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Maa MC, et al. (2010) Butyrate reduced lipopolysaccharide-mediated macrophage migration by suppression of Src enhancement and focal adhesion kinase activity. J. Nutr. Biochem. 21:1186–92.CrossRefGoogle Scholar
  49. 49.
    Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718–28.CrossRefGoogle Scholar
  50. 50.
    Choi Y, et al. (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp. Mol. Med. 40:574–81.CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Lal G, et al. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182:259–273.CrossRefPubMedCentralGoogle Scholar
  52. 52.
    Polansky JK, et al. (2008) DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38:1654–63.CrossRefGoogle Scholar
  53. 53.
    Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66:1277–81.CrossRefGoogle Scholar
  54. 54.
    Schickel R, Boyerinas B, Park SM, Peter ME (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959–74.CrossRefGoogle Scholar
  55. 55.
    Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD. (2008) MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9:839–45.CrossRefGoogle Scholar
  56. 56.
    Faraco G, et al. (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol. Dis. 36:269–79.CrossRefGoogle Scholar
  57. 57.
    Kiernan R, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758–66.CrossRefGoogle Scholar
  58. 58.
    Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–96.CrossRefGoogle Scholar
  59. 59.
    Shibata W, et al. (2007) Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 179:2681–5.CrossRefGoogle Scholar
  60. 60.
    Nenci A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:557–61.CrossRefGoogle Scholar
  61. 61.
    Chen L, Fischle W, Verdin E, Greene WC. (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 293:1653–7.CrossRefGoogle Scholar
  62. 62.
    Ashburner BP, Westerheide SD, Baldwin AS Jr. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065–77.CrossRefPubMedCentralGoogle Scholar
  63. 63.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M. (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 66:5409–18.CrossRefGoogle Scholar
  64. 64.
    Liu H, et al. (2006) Trichostatin A regulates hGCN5 expression and cell cycle on daudi cells in vitro. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26:534–7.CrossRefGoogle Scholar
  65. 65.
    Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J. Biol. Chem. 281:5612–22.CrossRefGoogle Scholar
  66. 66.
    Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613–622.CrossRefGoogle Scholar
  67. 67.
    Kramer OH, et al. (2006) Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20:473–485.CrossRefPubMedCentralGoogle Scholar
  68. 68.
    Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015–22.CrossRefGoogle Scholar
  69. 69.
    Marks PA, Dokmanovic M. (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs. 14:1497–511.CrossRefGoogle Scholar
  70. 70.
    Bertrand P. (2010) Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem. 45:2095–116.CrossRefGoogle Scholar
  71. 71.
    Reilly CM, et al. (2008) The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31:123–30.CrossRefGoogle Scholar
  72. 72.
    Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99–104.CrossRefPubMedCentralGoogle Scholar
  73. 73.
    Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1–15.CrossRefPubMedCentralGoogle Scholar
  74. 74.
    Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281–90.CrossRefGoogle Scholar
  75. 75.
    Boirivant M, Fuss IJ, Chu A, Strober W. (1998) Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188:1929–39.CrossRefPubMedCentralGoogle Scholar
  76. 76.
    Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8.CrossRefGoogle Scholar
  77. 77.
    Neurath MF, et al. (2001) Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22:21–6.CrossRefGoogle Scholar
  78. 78.
    Lugering A, et al. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology. 121:1145–57.CrossRefGoogle Scholar
  79. 79.
    Tanaka T, et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94:965–73.CrossRefGoogle Scholar
  80. 80.
    Hegazi RA, et al. (2003) Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm. Bowel Dis. 9:230–36.CrossRefGoogle Scholar
  81. 81.
    Chateauvieux S, Morceau F, Dicato M, Diederich M. (2010) Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010:479364.CrossRefPubMedCentralGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  1. 1.Medizinische Klinik ICharite-Universitätsmedizin Berlin, Campus Benjamin FranklinBerlinGermany

Personalised recommendations